Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

ClinicalTrials.gov ID: NCT03463187

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03463187. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 6:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.

Study identification

NCT ID
NCT03463187
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
211 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 15, 2017 (Actual)
Primary completion
Aug 31, 2020 (Actual)
Completion
Aug 31, 2020 (Actual)
Last update posted
Aug 8, 2023

2017 – 2020

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Elite Clinical Studies, LLC Phoenix Arizona 85018 —
Anaheim Clinical Trials Anaheim California 92801 —
Revival Research Doral Florida 33122 —
Indago Research and Health Center - Emergency Medicine Hialeah Florida 33012 —
Great Lakes Clinical Trials LLC Chicago Illinois 60640 —
Clinical Partners, LLC Johnston Rhode Island 02919 —
Center for Clinical Studies Houston Texas 77004 —
Center for Clinical Studies Webster Texas 77598 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03463187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 8, 2023 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.